ANALYTICAL METHOD VALIDATION AND BIOEQUIVALENCE STUDY OF ERLOTINIB 150 MG TABLETS IN IRANIAN HEALTHY VOLUNTEERS UNDER FASTING CONDITION

GHASEMIAN ELHAM; SADRAI SIMA; SHOKRI JAVAD; ILKA A.

doi:10.22159/ijpps.2023v15i1.46475

Authors

GHASEMIAN ELHAM Department of Pharmaceutics, Faculty of Pharmacy, Islamic Azad University of Damghan, Damghan, Iran https://orcid.org/0000-0001-5262-0576
SADRAI SIMA Division of Biopharmaceutics and Pharmacokinetics, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
SHOKRI JAVAD Pharmaceutical department, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
ILKA A. Molecular Biology Department, Islamic Azad University, Tehran North Branch, Tehran, Iran

DOI:

https://doi.org/10.22159/ijpps.2023v15i1.46475

Keywords:

Bioequivalence, Pharmacokinetics, Lung cancer, Erlotinib, LC-MS/MS

Abstract

Objective: This study aims to compare a generic formulation of the drug erlotinib 150 mg tablet to the brand-name version to validate the analytical method and bioequivalence studies.

Methods: Erlotinib hydrochloride tablets (test versus reference formulation) were compared in a randomized, two-period crossover study to determine their pharmacokinetic properties and bioequivalence in healthy Iranian volunteers. 14 d passed between each treatment during the washout period. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to analyze erlotinib, and the method validation is presented.

Results: Over the range of 6.25-3200 ng/ml, the analytical method was verified as linear (R2= 0.998). The technique was also accurate and precise at various concentrations. The results showed that the pharmacokinetics of the two products were comparable. Following administration of the test and reference products, the geometric averages for (Area under the curve) AUC_0-72, AUC_inf, and maximum plasma concentration (C_max) were 104.71 (90% CI, 93.39-117.40), 104.68 (90% CI, 93.47-117.23), and 104.85 (90% CI, 94.61-116.21), respectively. The outcomes fell within the permitted tolerance of 0.8 to 1.25.

Conclusion: For the determination of erlotinib in plasma, the used analytical approach is accurate, precise, repeatable, and selective. Additionally, the bioequivalence research revealed no appreciable differences in pharmacokinetic characteristics between the reference and test products. Therefore, it is possible to assert that the generic erlotinib product and the reference product are bioequivalent.

Downloads

Download data is not yet available.

References

Gridelli C, Bareschino MA, Schettino C, Rossi A, Maione P, Ciardiello F. Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist. 2007;12(7):840-9. doi: 10.1634/theoncologist.12-7-840, PMID 17673615.

Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist. 2005;10(7):461-6. doi: 10.1634/theoncologist.10-7-461, PMID 16079312.

Lu JF, Eppler SM, Wolf J, Hamilton M, Rakhit A, Bruno R. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther. 2006;80(2):136-45. doi: 10.1016/j.clpt.2006.04.007, PMID 16890575.

Christiansen SR, Broniscer A, Panetta JC, Stewart CF. Pharmacokinetics of erlotinib for the treatment of high-grade glioma in a pediatric patient with cystic fibrosis: case report and review of the literature. Pharmacotherapy. 2009;29(7):858-66. doi: 10.1592/phco.29.7.858, PMID 19558260.

Erdogar N. Development of oral tablet formulation containing erlotinib: randomly methylated-β-cyclodextrin inclusion complex using direct compression method. Turk J Pharm Sci. 2021;18(5):589-96. doi: 10.4274/tjps.galenos.2021.95680, PMID 34719186.

Tarceva (Package insert) Genentech, Inc. Revised. Vols; 2014.

Gruber A, Czejka M, Buchner P, Kitzmueller M, Kirchbaumer Baroian N, Dittrich C. Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model. Cancer Chemother Pharmacol. 2018;81(4):763-71. doi: 10.1007/s00280-018-3545-4, PMID 29453635.

Ling J, Johnson KA, Miao Z, Rakhit A, Pantze MP, Hamilton M. Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos. 2006;34(3):420-6. doi: 10.1124/dmd.105.007765, PMID 16381666.

Jawhari D. Bioequivalence of a new generic formulation of erlotinib hydrochloride 150 mg tablets versus tarceva in healthy volunteers under fasting conditions. J Bioequiv Availab 2014;6(4):119-23. doi: 10.4172/jbb.1000190.

Broniscer A, Baker SJ, Stewart CF, Merchant TE, Laningham FH, Schaiquevich P. Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. Clin Cancer Res. 2009;15(2):701-7. doi: 10.1158/1078-0432.CCR-08-1923, PMID 19147777.

Prados MD, Lamborn KR, Chang S, Burton E, Butowski N, Malec M. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol. 2006;8(1):67-78. doi: 10.1215/S1522851705000451, PMID 16443950.

Jahangiri A, Khalilzad F, Barghi L. Dissolution improvement of binary solid dispersions of erlotinib prepared by one-step electrospray method. Biol Methods Protoc. 2022;7(1):bpac001. doi: 10.1093/biomethods/bpac001, PMID 35111974.

Bioanalytical method validation guidance for industry. Center for Drug Evaluation and Research (CDER): Food and Drug Administration; 2018. Available from: https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf.

Guidance for industry Q2B validation of analytical procedures: methodology. Geneva; 1996. Available from: https://www.fda.gov/media/71725/download.

Tijare LK, Nt R, Un M. A review on bioanalytical method development and validation. Asian J Pharm Clin Res. 2016;9(9)Suppl 3:6-10. doi: 10.22159/ajpcr.2016.v9s3.14321.

Wenkui L, Ying HL, Austin C, Shaolin Z, Weng N. Simultaneous determination of norethindrone and ethinyl estradiol in human plasma by high-performance liquid chromatography with tandem mass spectrometry-experience on developing a highly selective method using derivatization reagent for enhancing sensitivity. J Chromatogr B. 2005;825:223-32.

Adluri P, Kumar YS. Development and validation of sensitive LC-ESI-MS/MS method for the simultaneous estimation of Dapagliflozin and saxagliptin in human plasma. Int J Pharm Pharm Sci. 2019;11:55-9.

Erlotinib film-coated tablets 25, 100 and 150-mg product-specific bioequivalence guidance*, EMA/CHMP/675840/2014; 2014.

Wang L, Ruan Z, Yang D, Hu Y, Liang J, Chen J. Pharmacokinetics and bioequivalence evaluation of erlotinib hydrochloride tablets: randomized, open-label, 2-period crossover study in healthy Chinese subjects. Clin Pharmacol Drug Dev. 2021;10(2):166-72. doi: 10.1002/cpdd.811, PMID 32416055.

Frohna P, Lu J, Eppler S, Hamilton M, Wolf J, Rakhit A. Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects. J Clin Pharmacol. 2006;46(3):282-90. doi: 10.1177/0091270005284193, PMID 16490804.

Public Assessment Report Scientific discussion erlotinib Waverley 25 mg, 100 mg and 150-mg film-coated tablets (erlotinib hydrochloride) NL/H/4179/001-003/DC Date. Available from: https://www.geneesmiddeleninformatiebank.nl/pars/h121920.pdf. [Last accessed on 11 Feb 2020]

Public Assessment Report Scientific discussion erlotinib Medical Valley erlotinib, erlotinib hydrochloride SE/H/2233/01-03/DC. Available from: https://docetp.mpa.se/lMF/Erlotinib%20Medical%20Valley%2025%20mg%20film-coated%20tablet%20ENG%20PAR_09001bee8250cdb3.pdf.